Limits...
Myocardial metastases on 6-[18F] fluoro-L-DOPA PET/CT: a retrospective analysis of 116 serotonin producing neuroendocrine tumour patients.

Noordzij W, van Beek AP, Tio RA, van der Horst-Schrivers AN, de Vries EG, van Ginkel B, Walenkamp AM, Glaudemans AW, Slart RH, Dierckx RA - PLoS ONE (2014)

Bottom Line: The diagnostic method of choice remains echocardiography.Laboratory tests and transthoracic echocardiography (TTE) results were digitally collected. 116 patients (62 male) underwent 18F-FDOPA PET/CT, mean age was 61±13 years.TTE was performed in 79 patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

ABSTRACT

Purpose: This study evaluates the prevalence of cardiac metastases in patients with serotonin producing neuroendocrine tumours (NET), examined with 18F-FDOPA PET/CT, and the relationship of these metastases to the presence of carcinoid heart disease (CHD) based on echocardiography.

Background: CHD occurs in patients with serotonin producing NET. The diagnostic method of choice remains echocardiography. The precise prevalence of cardiac metastases is unknown given the limitations of standard technologies. Nuclear medicine modalities have the potential to visualize metastases of NET.

Methods: All patients who underwent 18F-FDOPA PET/CT because of serotonin producing NET between November 2009 and May 2012 were retrospectively analyzed. The presence of cardiac metastasis was defined as myocardial tracer accumulation higher than the surrounding physiological myocardial uptake. Laboratory tests and transthoracic echocardiography (TTE) results were digitally collected.

Results: 116 patients (62 male) underwent 18F-FDOPA PET/CT, mean age was 61±13 years. TTE was performed in 79 patients. Cardiac metastases were present in 15 patients, of which 10 patients also underwent TTE. One patient had both cardiac metastasis (only on 18F-FDOPA PET/CT) and echocardiographic signs of CHD. There were no differences in echocardiographic parameters for CHD between patients with and without cardiac metastases. TTE in none of the 79 patients showed cardiac metastases.

Conclusion: The prevalence of cardiac metastases detected with 18F-FDOPA PET/CT in this study is 13%. 18F-FDOPA PET/CT can visualize cardiac metastases in serotonin producing NET patients. There appears to be no relationship between the presence of cardiac metastases and TTE parameters of CHD.

Show MeSH

Related in: MedlinePlus

CONSORT diagram.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4232397&req=5

pone-0112278-g001: CONSORT diagram.

Mentions: Patient selection is shown in Fig. 1.Of the 470 patients who underwent 18F-FDOPA PET/CT, those with medullary thyroid carcinoma, pheochromocytoma and paraganglioma (n = 202) were excluded. Of the remaining 268 patients with any form of NET, 116 patients had a serotonin producing NET. Of these patients 103 had a primary location in the small bowel, three a primary in lung, and in 10 patients the exact location of the primary tumour was unknown.


Myocardial metastases on 6-[18F] fluoro-L-DOPA PET/CT: a retrospective analysis of 116 serotonin producing neuroendocrine tumour patients.

Noordzij W, van Beek AP, Tio RA, van der Horst-Schrivers AN, de Vries EG, van Ginkel B, Walenkamp AM, Glaudemans AW, Slart RH, Dierckx RA - PLoS ONE (2014)

CONSORT diagram.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4232397&req=5

pone-0112278-g001: CONSORT diagram.
Mentions: Patient selection is shown in Fig. 1.Of the 470 patients who underwent 18F-FDOPA PET/CT, those with medullary thyroid carcinoma, pheochromocytoma and paraganglioma (n = 202) were excluded. Of the remaining 268 patients with any form of NET, 116 patients had a serotonin producing NET. Of these patients 103 had a primary location in the small bowel, three a primary in lung, and in 10 patients the exact location of the primary tumour was unknown.

Bottom Line: The diagnostic method of choice remains echocardiography.Laboratory tests and transthoracic echocardiography (TTE) results were digitally collected. 116 patients (62 male) underwent 18F-FDOPA PET/CT, mean age was 61±13 years.TTE was performed in 79 patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

ABSTRACT

Purpose: This study evaluates the prevalence of cardiac metastases in patients with serotonin producing neuroendocrine tumours (NET), examined with 18F-FDOPA PET/CT, and the relationship of these metastases to the presence of carcinoid heart disease (CHD) based on echocardiography.

Background: CHD occurs in patients with serotonin producing NET. The diagnostic method of choice remains echocardiography. The precise prevalence of cardiac metastases is unknown given the limitations of standard technologies. Nuclear medicine modalities have the potential to visualize metastases of NET.

Methods: All patients who underwent 18F-FDOPA PET/CT because of serotonin producing NET between November 2009 and May 2012 were retrospectively analyzed. The presence of cardiac metastasis was defined as myocardial tracer accumulation higher than the surrounding physiological myocardial uptake. Laboratory tests and transthoracic echocardiography (TTE) results were digitally collected.

Results: 116 patients (62 male) underwent 18F-FDOPA PET/CT, mean age was 61±13 years. TTE was performed in 79 patients. Cardiac metastases were present in 15 patients, of which 10 patients also underwent TTE. One patient had both cardiac metastasis (only on 18F-FDOPA PET/CT) and echocardiographic signs of CHD. There were no differences in echocardiographic parameters for CHD between patients with and without cardiac metastases. TTE in none of the 79 patients showed cardiac metastases.

Conclusion: The prevalence of cardiac metastases detected with 18F-FDOPA PET/CT in this study is 13%. 18F-FDOPA PET/CT can visualize cardiac metastases in serotonin producing NET patients. There appears to be no relationship between the presence of cardiac metastases and TTE parameters of CHD.

Show MeSH
Related in: MedlinePlus